Moleculin said Annamycin data were accepted for a future meeting, but it did not report the data. The scheduled presentation does not show whether the drug helps patients or changes the company's prospects.
This could give Annamycin more visibility among blood cancer researchers. The filing shares no study findings or patient outcomes, so it does not show that the drug works or change what is known about Moleculin's prospects.
Follow Moleculin Biotech, Inc. (MBRX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MBRX